Akela reports net gain of $1.

Akela reports net gain of $1.5 million for three months ended December 31, 2010 Akela Pharma, Inc. , a innovator in the advancement of therapeutics for the treatment of pain, and the company’s wholly possessed subsidiary, PharmaForm, announced its financial outcomes for the 90 days and year finished December 31 today, 2010 premature ejection . December 31 Total consolidated revenues for the 90 days ended, 2010 were $3.7 million, including $3.0 million of contract companies, when compared with $3.0 million, including $2.4 million of contract companies, for the same period through the prior year.3 million, including $10.2 million of contract services, when compared with $13.9 million, including $10.6 million of contract companies, for 2009.